Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Guidant Will Share RX Stent Delivery With Abbott If Guidant Deal Closes

This article was originally published in The Gray Sheet

Executive Summary

Abbott could be a strong player in the drug-eluting stent market by 2007 if the J&J/Guidant merger is completed as required by FTC
Advertisement

Related Content

Zoll’s AutoPulse CPR-Assist Device Helps Resuscitate Stock, Up 24% In Q2
Zoll’s AutoPulse CPR-Assist Device Helps Resuscitate Stock, Up 24% In Q2
Guidant Accepts Yet Another J&J Bid As Takeover War Escalates
Guidant Accepts Yet Another J&J Bid As Takeover War Escalates
J&J Salvages Deal With Guidant: $4 Bil. Shaved Off Purchase Price
J&J Salvages Deal With Guidant: $4 Bil. Shaved Off Purchase Price
Medtronic Misses Endeavor Primary Endpoint, But Claims PMA Still On Track
Bear Stearns Healthcare Conference In Brief
Abbott On Track To Reach U.S. DES Market By Late 2007 With ZoMaxx
Abbott On Track To Reach U.S. DES Market By Late 2007 With ZoMaxx
Advertisement
UsernamePublicRestriction

Register

MT022867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel